MYCOFIT is also known as Indian Generic Cellcept, is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac or hepatic transplants. MYCOFIT should be used concomitantly with cyclosporine and corticosteroids.
MYCOFIT Intravenous is an alternative dosage form to MYCOFIT capsules, tablets and oral suspension. MYCOFIT Intravenous should be administered within 24 hours following transplantation. MYCOFIT Intravenous can be administered for up to 14 days; patients should be switched to oral MYCOFIT as soon as they can tolerate oral medication.
Allergic reactions to MYCOFIT have been observed; therefore, MYCOFIT is contraindicated in patients with a hypersensitivity to mycophenolate mofetil, mycophenolic acid or any component of the drug product. MYCOFIT Intravenous is contraindicated in patients who are allergic to Polysorbate 80 (TWEEN).
The principal adverse reactions associated with the administration of MYCOFIT include diarrhea, leukopenia, sepsis, vomiting, and there is evidence of a higher frequency of certain types of infections eg, opportunistic infection. The adverse event profile associated with the administration of MYCOFIT Intravenous has been shown to be similar to that observed after administration of oral dosage forms of MYCOFIT.
MYCOFIT’s brand name in usa is CellCept by Roche. MYCOFIT is a generic prescription medicine from Intas, which is one of the biggest pharmaceutical company in India.